Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer
Status:
Recruiting
Trial end date:
2025-08-15
Target enrollment:
Participant gender:
Summary
A single centre phase II trial of peri-operative chemo-immunotherapy in operable
gastro-oesophageal adenocarcinoma (GOA). This trial is designed to evaluate the safety and
efficacy of administering Avelumab, an anti-PD-L1 monoclonal antibody, with cytotoxic FLOT
chemotherapy for patients with operable GOA treated according to a peri-operative protocol.
This trial is in 2 stages: the first stage will establish the safe and tolerated maximum
administered dose (MAD) of Avelumab in combination with FLOT and the second stage will assess
the efficacy of this combination therapy in achieving pathological complete response (pCR)
and peri-operative safety.